B-cell treatment linked to more gut immune cells in MS
By MS Buddy ·
Summarized from Science translational medicine, Jul 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Observational study · people with MS, a person without MS, and mice
Research by Tradite Neziraj, Anne-Katrin Pröbstel and 26 colleagues at the University of Toronto, Vrije Universiteit and 5 other institutions in Switzerland, Canada, the Netherlands and 2 other countries.
How does B-cell treatment affect gut-linked immune cells in MS?
Key Takeaway
During B-cell treatment, people with MS had more gut-linked immune cells in their blood and spinal fluid.

What They Found
Researchers tracked immune cells during treatment that removes B cells, a type of immune cell. They found more B cells linked to the gut in the blood and spinal fluid. Cell patterns suggested that some of these cells traveled from the gut to other parts of the body. Higher levels of two substances that help B cells survive and grow were linked to better outcomes during treatment. The study did not show whether the gut-linked cells caused those better outcomes.
Who Should Care and Why
Researchers studied people with MS, one person without MS, and mice with an MS-like disease. The human findings concern people with MS receiving treatment that removes B cells. The researchers examined blood, spinal fluid, and samples from the gut. Gut samples came from one person with MS receiving treatment and one person without MS. The findings may help explain immune changes seen during this treatment.
Important Considerations
You should know that gut samples came from only one person with MS and one person without MS. The abstract does not give the total number of people studied, and some spinal fluid findings came from earlier datasets. You cannot tell from this study whether the gut-linked cells improve MS outcomes.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Science translational medicine by et al.. Reproduced from the PubMed record.
Therapy with anti-CD20 monoclonal antibodies is highly efficacious in various autoimmune diseases including multiple sclerosis (MS), a prototypic autoimmune inflammatory disease of the central nervous system (CNS). However, which B cell subsets and altered B cell-regulating factors mediate the clinical efficacy of anti-CD20 treatment is unclear. To address this gap in knowledge, we performed longitudinal high-dimensional single-cell transcriptomic and proteomic profiling of blood, cerebrospinal fluid (CSF), and intestinal samples from people with MS (pwMS), combined with immune profiling in a preclinical autoimmune encephalomyelitis model during anti-CD20 therapy. CSF analyses were performed using previously published datasets. Multisite intestinal profiling was conducted in one anti-CD20-treated patient with MS and one control participant. By applying algorithm-guided analyses of flow cytometry, single-cell transcriptomic, and immune receptor repertoire data, we found that anti-CD20 B cell depletion was associated with increased frequencies of regulatory mucosal-derived IgA-producing B cells in the periphery and CSF, together with increased B cell receptor clonal overlap between mucosal and systemic compartments, indicating enhanced trafficking of IgA B cells from gut mucosal tissues to the systemic circulation and the CNS. Moreover, we demonstrated that higher levels of B cell-activating factor and a proliferation-inducing ligand were related to favorable outcomes in pwMS during anti-CD20 treatment. Together, our findings suggest that mucosal immune regulatory mechanisms may be harnessed by anti-CD20 B cell depletion, opening previously unknown therapeutic avenues for MS.
Categories
Explore more research
Related MS research

11/16/2026
A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS
Read More
11/14/2026
In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.
Read More
11/15/2026
In tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve e
Read More
11/15/2026
A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older
Read More
11/13/2026
A review compares MS with harmful drug reactions and proposes ways to test how immune genes, lasting
Read More
11/13/2026
This review examines how vitamin D and vitamin A signals shape immune activity in MS and other disea
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
